Watchlist Price Alert

Syndax Pharmaceuticals In... (SNDX)

NASDAQ: SNDX · Real-Time Price · USD

11.02

-0.18 (-1.56%)

At close: Jun 04, 2025, 10:03 AM

-1.56% (1D)

Bid	11.06
Market Cap	948.24M
Revenue (ttm)	43.72M
Net Income (ttm)	-331.2M
EPS (ttm)	-3.85
PE Ratio (ttm)	-2.86
Forward PE	-4.05
Analyst	Buy

Ask	11.1
Volume	59,028
Avg. Volume (20D)	2,582,935
Open	11.27
Previous Close	11.20
Day's Range	11.00 - 11.41
52-Week Range	8.58 - 25.07
Beta	0.74

About SNDX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SNDX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SNDX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

+7.47%

Syndax Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

3 months ago

-1.02%

Syndax Pharmaceuticals shares are trading lower after the company reported Q4 financial results and missed its EPS and sales estimate.

News

3 weeks ago · zacks.com

Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?

The consensus price target hints at a 220% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate re...

4 weeks ago · seekingalpha.com

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - Chief Executive Officer and Direct...

4 weeks ago · zacks.com

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $0.85 per share a year ago.